StonvexLoading…
StonvexStonvexStonvexCore line items from HCAT's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $311.14M | $306.58M | $295.94M | $276.24M |
Operating Income | $-160.85M | $-69.81M | $-126.90M | $-140.00M |
Net Income | $-177.97M | $-69.50M | $-118.15M | $-137.40M |
EPS (Diluted) | $-2.55 | $-1.15 | $-2.09 | $-2.63 |
Total Assets | $502.64M | $858.93M | $701.81M | $752.29M |
Total Liabilities | $256.86M | $493.72M | $334.89M | $327.28M |
Cash & Equivalents | $50.81M | $249.65M | $106.28M | $116.31M |
Free Cash Flow OCF − CapEx | $-237.00K | $12.94M | $-34.32M | $-37.44M |
Shares Outstanding | 72.03M | 64.04M | 58.30M | 55.26M |